The short version of Heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
The magnetron method: Using a GRD7 Valve (Ferranti valve), electrons are expelled from a hot tungsten-wire filament towards an anode. The electron is then deflected using a solenoid. From the current in the solenoid and the current in the Ferranti Valve, e/m can be calculated. Fine beam tube method: A heater heats a cathode, which emits electrons. The electrons are accelerated through a known potential, so the velocity of the electrons is known. The beam path can be seen when the electrons are accelerated through a helium (He) gas. The collisions between the electrons and the helium gas produce a visible trail. A pair of Helmholtz coils produces a uniform and measurable magnetic field at right angles to the electron beam. This magnetic field deflects the electron beam in a circular path. By measuring the accelerating potential (volts), the current (amps) to the Helmholtz coils, and the radius of the electron beam, e/m can be calculated.
==== Executive Committee ==== The Executive Committee of the IIR handles the administrative and financial aspects of the daily running of the IIR and meets once per year. It includes one delegate per member country, a president and three to six vice-presidents.
== El Salvador == In the 1980s, U.S. Army Special Forces trainers were deployed to El Salvador. Their mission was to train the Salvadoran Military, who at the time were fighting a civil war against the left-wing guerrillas of the Farabundo Marti National Liberation Front (FMLN). In 1992, the FMLN reached a ceasefire agreement with the government of El Salvador. Following the success of SF in El Salvador, the 3rd Special Forces Group was reactivated in 1990.
Sources: en.wikipedia.org
A vaccine vial monitor (VVM) is a time temperature indicator put on vials containing vaccines which gives a visual indication of whether the vaccine has been kept at a temperature which preserves its potency. A VVM slowly changes color as it is exposed to heat, accelerating as the environment gets hotter. The VVM helps healthcare workers determine a vaccine left out of the cold chain is still effective. Many of vaccines can survive days even at a scorching 40 °C (104 °F), but without a VVM there is no way to tell whether a vaccine has been destroyed by spending too many days sitting hot. The VVM provides that information and allows this type of operation (controlled temperature chain) to be safely conducted. This is especially important when delivering vaccines to developing countries where the cold chain is difficult to preserve.
=== Shrinkage and swelling === Shrinkage and swelling may occur in wood when the moisture content is changed. Shrinkage occurs as moisture content decreases, while swelling takes place when it increases. Volume change is not equal in all directions. The greatest dimensional change occurs in a direction tangential to the growth rings. Shrinkage from the pith outwards, or radially, is usually considerably less than tangential shrinkage, while longitudinal (along the grain) shrinkage is so slight as to be usually neglected. The longitudinal shrinkage is 0.1% to 0.3%, in contrast to transverse shrinkages, which is 2% to 10%. Tangential shrinkage is often about twice as great as in the radial direction, although in some species it is as much as five times as great. The shrinkage is about 5% to 10% in the tangential direction and about 2% to 6% in the radial direction. Differential transverse shrinkage of wood is related to:
Castro believed the failed raid indicated that the US and South Africa were not truly committed to peace, and had been dishonest during the ceasefire negotiations. Angola announced it was no longer willing to consider a line of dialogue with South Africa on the Cuban withdrawal. The US condemned Operation Argon as an "unfriendly act by a supposedly friendly government".
Sources: en.wikipedia.org
Counter-Strike was the most successful, having been released in six different editions: as a standalone product (2000), as part of the Platinum Pack (2000), as an Xbox version (2003), and as a single-player spin-off, Counter-Strike: Condition Zero (2004), as well as in two versions using the Source engine. Team Fortress Classic, Day of Defeat, Gunman Chronicles (2000, a futuristic Western movie-style total conversion with emphasis on its single-player mode) and Sven Co-op were also released as standalone products. Half-Life is also the subject of the YouTube improv roleplaying series Half-Life VR but the AI is Self-Aware and Freeman's Mind. In 2003, Valve's network was infiltrated by hackers. Among the stolen files was the unreleased Half-Life mod Half-Life: Threewave, a canceled remake of the Quake mod Threewave CTF. The files were found by fans on a Vietnamese FTP server in February 2016 and unofficially distributed that September.
== Interactions == Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves. It may also potentiate the CNS depressant effects of alcohol. It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbital) and itself. It may also interact with:
At the beginning of June 1976, the King visited the United States and in his speech before Congress, of whose exact content Arias Navarro was not aware, he ratified his commitment to provide Spain with a full democracy. Juan Carlos announced the Crown's will to "ensure the access to power of the different government alternatives, according to the freely expressed wishes of the Spanish people". A month and a half earlier, Newsweek magazine had claimed that King Juan Carlos had told one of its journalists ─ which was never denied ─ that "Arias was an unmitigated disaster". Around the same time Arias Navarro had made a statement on television in which he had made harsh attacks on the democratic opposition, while his relations with the king had deteriorated to the point that Arias had confessed to one of his closest collaborators: "It happens to me like with children; I can't stand him for more than ten minutes". After commenting to Areilza "this cannot go on, at the risk of losing everything ...", Juan Carlos demanded Arias Navarro on July 1 to present his resignation, which he did immediately. A few days later, Torcuato Fernández Miranda succeeded in getting the Council of the Realm to include among the three aspirants for President of the Government the "king's candidate": Adolfo Suárez, a "blue reformist" who had not stood out too much until then. Suárez's appointment caused enormous bewilderment and disappointment among the democratic opposition and diplomatic circles, as well as in newspaper editorial offices.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.